메뉴 건너뛰기




Volumn 14, Issue 8, 2009, Pages 800-805

Sorafenib and Sunitinib (Oncologist (2009) 14 (800-805) DOI: 10.1634/theoncologist.2009-0088);Sorafenib and sunitinib

Author keywords

Drug profile; Sorafenib; Sunitinib

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CARBOPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; FLUOROURACIL; GEMCITABINE; KETOCONAZOLE; OXALIPLATIN; PACLITAXEL; PLACEBO; RIFAMPICIN; SORAFENIB; SU 12662; SUNITINIB; UNCLASSIFIED DRUG;

EID: 70249091524     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0088erratum     Document Type: Erratum
Times cited : (51)

References (25)
  • 1
    • 34547459725 scopus 로고    scopus 로고
    • Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer
    • DOI 10.1592/phco.27.8.1125
    • Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-1144. (Pubitemid 47173659)
    • (2007) Pharmacotherapy , vol.27 , Issue.8 , pp. 1125-1144
    • Grandinetti, C.A.1    Goldspiel, B.R.2
  • 2
    • 60549098640 scopus 로고    scopus 로고
    • Sorafenib: A review of its use in advanced hepatocellular carcinoma
    • Keating GM, Santoro A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-240.
    • (2009) Drugs , vol.69 , pp. 223-240
    • Keating, G.M.1    Santoro, A.2
  • 3
    • 33845323729 scopus 로고    scopus 로고
    • Sunitinib
    • discussion 2267-2268.
    • Deeks ED, Keating GM. Sunitinib. Drugs 2006;66:2255-2266; discussion 2267-2268.
    • (2006) Drugs , vol.66 , pp. 2255-2266
    • Deeks, E.D.1    Keating, G.M.2
  • 4
    • 70249113967 scopus 로고    scopus 로고
    • [package insert]. West Haven, CT: Bayer Healthcare
    • Nexavar® (sorafenib) [package insert]. West Haven, CT: Bayer Healthcare, 2005.
    • (2005) Nexavar® (Sorafenib)
  • 6
    • 70249146063 scopus 로고    scopus 로고
    • [package insert]. New York, NY: Pfizer Labs
    • Sutent® (sunitinib) [package insert]. New York, NY: Pfizer Labs, 2006.
    • (2006) Sutent® (Sunitinib)
  • 7
    • 0035226814 scopus 로고    scopus 로고
    • Protein kinase-mediated signaling networks. Regulation and functional characterization
    • Reith AD. Protein kinase-mediated signaling networks. Regulation and functional characterization. Methods Mol Biol 2001;124:1-20.
    • (2001) Methods Mol Biol , vol.124 , pp. 1-20
    • Reith, A.D.1
  • 9
    • 44849093414 scopus 로고    scopus 로고
    • A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
    • Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007;18(suppl 10):x3-x10.
    • (2007) Ann Oncol , vol.18 , Issue.SUPPL. 10
    • Christensen, J.G.1
  • 11
    • 37749052511 scopus 로고    scopus 로고
    • Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma
    • Jain L, Gardner ER, Venitz J et al. Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal 2008;46:362-367.
    • (2008) J Pharm Biomed Anal , vol.46 , pp. 362-367
    • Jain, L.1    Gardner, E.R.2    Venitz, J.3
  • 12
    • 34247857540 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
    • DOI 10.1634/theoncologist.12-4-426
    • Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. The Oncologist 2007;12:426-437. (Pubitemid 46698720)
    • (2007) Oncologist , vol.12 , Issue.4 , pp. 426-437
    • Strumberg, D.1    Clark, J.W.2    Awada, A.3    Moore, M.J.4    Richly, H.5    Hendlisz, A.6    Hirte, H.W.7    Eder, J.P.8    Lenz, H.-J.9    Schwartzh, B.10
  • 14
    • 33645648696 scopus 로고    scopus 로고
    • Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
    • Lathia C, Lettieri J, Cihon F et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-692.
    • (2006) Cancer Chemother Pharmacol , vol.57 , pp. 685-692
    • Lathia, C.1    Lettieri, J.2    Cihon, F.3
  • 15
    • 34548310428 scopus 로고    scopus 로고
    • Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors
    • DOI 10.1016/j.clinthera.2007.07.022, PII S0149291807002147
    • Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-1353. (Pubitemid 47348120)
    • (2007) Clinical Therapeutics , vol.29 , Issue.7 , pp. 1338-1353
    • Adams, V.R.1    Leggas, M.2
  • 16
    • 70249098383 scopus 로고    scopus 로고
    • The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011249 pharmacokinetics (PK) in Caucasian and Asian healthy subjects
    • abstract 553
    • Washington C, Eli M, Bello C et al. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011249 pharmacokinetics (PK) in Caucasian and Asian healthy subjects [abstract 553]. Proc Am Soc Clin Oncol 2003;22.
    • (2003) Proc Am Soc Clin Oncol , vol.22
    • Washington, C.1    Eli, M.2    Bello, C.3
  • 17
    • 33745148889 scopus 로고    scopus 로고
    • Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers
    • abstract
    • Bello C, Houk B, Sherman L et al. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers [abstract]. Proc Am Soc Clin Oncol 2005;23(16 suppl):3078.
    • (2005) Proc Am Soc Clin Oncol , vol.23 , Issue.16 SUPPL. , pp. 3078
    • Bello, C.1    Houk, B.2    Sherman, L.3
  • 18
    • 33646204716 scopus 로고    scopus 로고
    • Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
    • Richly H, Henning BF, Kupsch P et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-873.
    • (2006) Ann Oncol , vol.17 , pp. 866-873
    • Richly, H.1    Henning, B.F.2    Kupsch, P.3
  • 20
    • 64649083367 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
    • Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-1805.
    • (2009) J Clin Oncol , vol.27 , pp. 1800-1805
    • Miller, A.A.1    Murry, D.J.2    Owzar, K.3
  • 21
    • 34248585901 scopus 로고    scopus 로고
    • Sorafenib: Delivering a targeted drug to the right targets
    • Flaherty KT. Sorafenib: Delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007;7:617-626.
    • (2007) Expert Rev Anticancer Ther , vol.7 , pp. 617-626
    • Flaherty, K.T.1
  • 23
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 24
    • 33749505836 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
    • Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
    • (2006) Lancet , vol.368 , pp. 1329-1338
    • Demetri, G.D.1    Van Oosterom, A.T.2    Garrett, C.R.3
  • 25
    • 38549085315 scopus 로고    scopus 로고
    • Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis
    • Wu S, Chen JJ, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008;9:117-123.
    • (2008) Lancet Oncol , vol.9 , pp. 117-123
    • Wu, S.1    Chen, J.J.2    Kudelka, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.